IL43751A - Des-lys29-ala30-insulins and their preparation - Google Patents
Des-lys29-ala30-insulins and their preparationInfo
- Publication number
- IL43751A IL43751A IL43751A IL4375173A IL43751A IL 43751 A IL43751 A IL 43751A IL 43751 A IL43751 A IL 43751A IL 4375173 A IL4375173 A IL 4375173A IL 43751 A IL43751 A IL 43751A
- Authority
- IL
- Israel
- Prior art keywords
- insulin
- des
- lys
- enzyme
- porcine
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000004026 insulin derivative Substances 0.000 title description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 95
- 102000004190 Enzymes Human genes 0.000 claims description 43
- 108090000790 Enzymes Proteins 0.000 claims description 43
- 108010005991 Pork Regular Insulin Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 33
- 102000004877 Insulin Human genes 0.000 claims description 31
- 108090001061 Insulin Proteins 0.000 claims description 31
- 229940125396 insulin Drugs 0.000 claims description 29
- 101001011741 Bos taurus Insulin Proteins 0.000 claims description 28
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 108091005804 Peptidases Proteins 0.000 claims description 20
- 239000004365 Protease Substances 0.000 claims description 20
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 19
- 239000004472 Lysine Substances 0.000 claims description 18
- 238000011534 incubation Methods 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 claims description 16
- 239000000758 substrate Substances 0.000 claims description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 11
- 229920005654 Sephadex Polymers 0.000 claims description 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 9
- 239000012736 aqueous medium Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 5
- 239000007972 injectable composition Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 3
- 239000002808 molecular sieve Substances 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- MPZWMIIOPAPAKE-BQBZGAKWSA-N Glu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N MPZWMIIOPAPAKE-BQBZGAKWSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910001425 magnesium ion Inorganic materials 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 24
- 235000019419 proteases Nutrition 0.000 description 18
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 13
- 239000001099 ammonium carbonate Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000011054 acetic acid Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000001110 calcium chloride Substances 0.000 description 8
- 229910001628 calcium chloride Inorganic materials 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002608 insulinlike Effects 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000012501 ammonium carbonate Nutrition 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- MJQHZNBUODTQTK-WKGBVCLCSA-N (2s,3r,4s,5r,6r)-2-[[(1s,3s,4s,5s,8r)-3-[(2s,3r,4s,5s,6r)-2-[[(1s,3r,4s,5s,8r)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5- Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H]2OC[C@@H]1O[C@@H](O[C@@H]1[C@H]([C@H](O[C@H]3[C@H]4OC[C@@H]3O[C@@H](O)[C@H]4O)O[C@H](CO)[C@@H]1O)O)[C@H]2O MJQHZNBUODTQTK-WKGBVCLCSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 241001544324 Myxobacter Species 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101710180316 Protease 2 Proteins 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- APJDWQBUKADMHV-UHFFFAOYSA-N 2-[(4,6-dichloro-1,3,5-triazin-2-yl)azaniumyl]acetate Chemical compound OC(=O)CNC1=NC(Cl)=NC(Cl)=N1 APJDWQBUKADMHV-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OMSMPWHEGLNQOD-UWVGGRQHSA-N Asn-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UWVGGRQHSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- -1 oligopeptides Chemical compound 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
43751/2 -ALA -INSULINS AND THEIR PREPARATION 30 29 ojioni o>a»i>ioa>K-Alta -Lys _0-, This invention relates to polypeptides and in particular it relates to polypeptides obtained by modification of porcine or bovine insu^i It is well known that administration of insulin is of immense value in the management of diabetes in humans. For this purpose, the insulin normally used is obtained from pigs, so-called "porcine insulin" or from cows^ so-called "bovine insulin". It is also known that administration of either porcine insulin or bovine insulin, as normally available, often causes an antigenic response. In humans, this antigenic response can lead, over a prolonged period of dosing, to an increase in the daily dose required by the diabetic patient to control the disease.
The only difference between porcine insulin and human insulin is at position 30 of the B chain, and this is also the position of one of the differences between bovine insulin and human insulin. Further, there is only one lysine residue in the insulin molecule and it is at position 29 of the B chain. Thus if porcine insulin or bovine insulin could be cleaved by an enzyme which is specific for the peptide bond attached to the amino group of lysine, i.e. a lysine specific aminoendopeptidaae, then the polypeptide obtained from porcine insulin would have the same sequence as the corresponding part of human insulin and the polypeptide obtained from bovine insulin would differ from human insulin in one less respect.
It has now been discovered, and this is the basis of the present invention, that if porcine or bovine insulin, as normally available, is treated with a lysine specific aminoendopeptidase, that is a peptidase which cleaves a polypeptide at the peptide link attached to the amino group of lysine and does not require the lysine residue to be at the C-terminus of the peptide chain, then the products obtained are as potent as porcine or bovine insulin in causing a hypoglycaemic response, and furthermore, each of them causes a significantly smaller production of antibodies which bind insulin-like materials on subsequent administration than does the initial porcine or bovine insulin respectively. The enzyme removes the dipeptide L-lysyl-L-alanine from the C-terminus of the B chain of the porcine or bovine insulin, and the polypeptides so obtained have not been described previously.
According to the invention there is provided a polypeptide of the formula :- .Asn Phe.Val.Asn.Gin.His.Leu.Cys.Gly.Ser.His.Leu.Val.Glu.Ala.Leu.lyr.lieu.Val.Cys.Gly.Glu -Arg.Gly.Phe.Phe.Tyr.1hr.Pro 1 2 1 wherein either R is threonine and R is isoleucine, or R is alanine and R is valine.
The polypeptide wherein R 1 is threonine and R2 is isoleucine differs from porcine insulin only in that the B chain, i.e. the longer chain, lacks the C-terminal lysyl and alanyl residues which form the 29th and 30th residues of the B chain of porcine insulin. This polypeptide can therefore be named 29 "50 des-Lys .Ala -porcine insulin, and this name will be used hereafter.
The polypeptide wherein R 1 is alanine and R2 is valine differs from bovine insulin only in that the B chain lacks the C-terminal lysyl and alanyl residues. It can therefore be named as des-Lys2^-Ala^°- bovine insulin, and this name will be used hereafter.
According to a further feature of the invention, there 29 "50 is provided a process for the preparation of des-Lys -Ala - porcine insulin from porcine insulin or of des-Lys29-Ala"30-bovine insulin from bovine insulin which comprises exposing the porcine or bovine insulin in an aqueous medium to the action of a lysine specific amino-endopeptidase followed by separation of the des-Lys 29-Ala30-porcine insulin or des-Lys29-Ala30-bovine insulin from the remaining enzyme and lysyl-alanine .
As examples of suitable lysine specific amino-endo-peptidases there may be mentioned the enzyme AM protease and the enzyme myxobacter AL-1 protease II.
The enzyme AM protease may be obtained from the mature fruiting bodies of the fungus Armi11aria me11ea as fully described and claimed in U.K. patent specification No. 1,263,956 , The enzyme may also be obtained, slightly more conveniently, by a modification of the procedure described in U.K. 1,263,956 in which the chromatography step (iv) is carried out in two stages: firstly by adsorbing the crude enzyme on carboxymethyl cellulose at pH 4. , and then eluting it with a pH 5· buffer and secondly by applying the concentrated eluate to the column described in step (iv) in the above patent.
The enzyme myxobacter AL-1 protease II may be obtained from myxobacter strain AL-1 as described by Wingard, Matsueda and Wolfe in the Journal of Bacteriology, Vol. 112, pages 40-949.
The exposure of the porcine or bovine insulin to the lysine specific amino-endopeptidase may be carried out with the enzyme simply dissolved in the aqueous medium, or it may be carried out with the enzyme bound to a support which may or may not be soluble in the aqueous medium.
The rate and extent of the reaction between the insulin used as starting material and the enzyme is dependent upon the enzyme /substrate ratio, the pH and temperature of the incubation medium, the concentration of insulin and the time of incubation. In general, of course, the time taken to cleave lysyl-alanine from the insulin used as starting material is shortened by an increase in either the concentration of the insulin or the enzyme /substrate ratio. Similarly, variation in the pH or temperature of the incubation medium affects the time needed to cleave the lysyl-alanine. The progress of the reaction may be monitored by examining samples of the reaction medium by either electrophoresis at pH 2.1 or separation on an automatic amino acid analyser, and so the desired end point of the reaction, that is essentially complete cleavage of lysyl-alanine, and the effect of any variation in the reaction conditions can readily be determined.
When the enzyme AM protease is used, the reaction will proceed at a wide variety of enzyme/substrate ratios, and indeed, as little as 1 part of enzyme to 10,000 parts of substrate can be used. The reaction will also proceed at a pH of the incubation medium from 3 to 10, and at a temperature from 10°C. to 60°C. With a given concentration of insulin, the reaction is fastest at a pH of from 4 to 9» but in the lower part of this pH range, the solubility of the insulin is relatively low so that a greater production of enzyme treated insulin is attainable at pH values in the higher part of the above range where the solubility of the insulin is greater. Accordingly, preferred reaction conditions to obtain essentially complete cleavage of lysyl-alanine in a relatively short period, for example 3-12 hours, are the use of a concentration of insulin near to its solubility in the incubation medium, a pH of from 7-9, a temperature of from 30°C. to 50°C. and as low an enzyme/substrate ratio as possible, for example 1/1,000 or less. It is also convenient to include metal ions in the incubation medium, for example calcium or magnesium in the form of their chlorides at a concentration 10 -2 to 10-4 molar.
When the enzyme myxobacter AL-1 protease II is used, the reaction conditions are very similar to those which may be used with AM protease; an enzyme/substrate ratio as low as 1/10,000 may be used at a pH from to 10 at a temperature from 25°C. to 75°C. Preferred conditions are the use of a concentration of insulin near to its solubility in the incubation medium, a pH of from 6 to 9, a temperature from 30°C. to 50°C, and as low an enzyme/substrate ratio as possible, for example 1/1,000 or less. Metal ions, for example calcium or magnesium may be included in the incubation medium.
As indicated above, the reaction may be carried out using; the enzyme bound, preferably covalently, to a support.
A variety of supports and methods of attachment are possible, and for details, a review by E. Katchalski in "Biochemical Aspects of Reactions on Solid Supports" ed. G.R. Stark, Academic Press 1971, should be consulted. One convenient method of attaching AM protease to a support is to activate agarose gel beads with cyanogen bromide, with or without spacer groups derived, for example, from hexylamine or hexanoic acid, and then allow the activated agarose to react with AM protease. Alternatively, the agarose gel beads may be activated using 2 ,4-dichloro-6-carboxymethylamino-s-triazine as coupling agent. Another useful alternative is the use of carboxymethyl cellulose hydrazide.
When the exposure to enzyme is carried out with the enzyme simply dissolved in the aqueous medium, the required des-Lys2^-Ala^°-porcine (or bovine) insulin may be separated from the other components of the incubation mixture by any conventional technique for the separation of polypeptides, but the use of a molecular sieve technique is particularly convenient. Thus, the aqueous medium remaining after all the starting insulin has been degraded may be filtered through a column of cross-linked dextran gel or a polyacrylamide gel suitable for fractionating compounds of molecular weight 5,000-10,000 at any convenient pH, preferably removed from, and preferably substantially below, the isoelectric point of the polypeptides, and the column eluted with a buffer composed of components which are volatile on freeze drying under high vacuum, for example aqueous acetic acid, ammonium carbonate or ammonium acetate, to give the desired product which is isolated by freeze drying the eluate.
When the exposure to enzyme is carried out with the enzyme bound to a support, separation of the required polypeptide from enzyme may be carried out by filtration in the normal way if the support is insoluble or using a filter for high polymers if the support is soluble in the aqueous medium.
As normally available, porcine or bovine insulin, even porcine or bovine insulin which has been crystallised several times, contains other polypeptides as impurities.
These impurities are usually present in an amount being 3-5% by weight of the whole, and consist of materials such as pro-insulin, pro-insulin fragments and glucagon which can be difficult to separate from the insulin. Since some at least of these impurities, on exposure to a lysine specific amino-endopeptidase , are degraded to smaller polypeptides, incubation of porcine or bovine insulin with a lysine specific amino-endopeptidase and separation of the product obtained from the enzyme, lysyl-alanine and polypeptides of smaller molecular weight than insulin, i.e. oligopeptides, leads to a product containing a smaller proportion of impurities than did the starting preparation. Since it is conceivable that the impurities present in an insulin preparation contribute to its antigenicity, exposure of the insulin preparation to a lysine specific amino-endopeptidase can affect the antigenicity of the starting material by modifying the structure of the principal component and by reducing the amount of impurities.
Thus according to a slightly different aspect of the invention there is provided a process for the conversion of porcine or bovine insulin as normally available into a product having insulin-like activity but being less effective in causing the production of antibodies which bind insulin-like materials on subsequent administration than does the starting material, which comprises exposing the porcine or bovine insulin in an aqueous medium to the action of a lysine specific amino-endopeptidase and separating the material with insulinlike activity from the enzyme ,lysyl-alanine and oligopeptides.
The incubation conditions and the isolation procedures are, of course, the same as described previously for the 29 30 29 preparation of des-Lys -Ala -porcine insulin or des-Lys -Ala bovine insulin.
As indicated above, the products and polypeptides of the invention have insulin-like activity and also cause a significantly smaller production of antibodies which bind insulin-like materials on subsequent administration than do the starting materials. The insulin-like activity is demonstrated by measuring the hypoglycaemic response produced by the products in rabbits using the technique set out in the United States Pharmacopeia, vol. 18, page 883. Equal weights of the products and the W.H.O. standard showed the same hypoglycaemic response within the accuracy of the method.
The smaller production of antibodies is demonstrated by administering the test compounds, dissolved in a 50:50 mixture of complete Preund's adjuvant and saline, to rabbits, and then, one month later, measuring the insulin binding capacity of the rabbit's serum by adding a known amount of insulin labelled with 1-125 to the serum and determining the amount of free and bound labelled insulin. This procedure is based on known methods, for example from Schlichtkrull et al. "Diabetes", vol. 21, Supplement 2, pages 649-656 (1972).
The new polypeptides of the invention are used for the management of diabetes in essentially the same way as porcine or bovine insulin. Thus they are administered parenterally, usually subcutaneously, either as a solution or as depot formulations having differing durations of action.
Such formulations allow for a duration of action for up to 24 hours. Doses are selected for individual patients as required for the control of the diabetic and may be as high as 200 units daily.
As a further feature of the invention there is provided an injectable formulation comprising des-Lys 29-Ala30- 29 30 porcine insulin or des-Lys -Ala -bovine insulin as the essential active ingredient.
The invention is illustrated but not limited by the following Examples in which the terms 'Sephadex' and ' Sepharose' are trade marks :- Example 1 Porcine insulin which had been re-crystallised 10 times (10 mg. ) was dissolved in 0.1 M ammonium bicarbonate (1.0 ml.) and the solution incubated with AM protease (50 g.) for 16 hours at ·37°0.
One aliquot (10 yl.) of the incubation mixture was then analysed for N-terminal amino-acids by the well-known "dansylation" technique using l-dimethylaminonaphthalene-5- sulphonyl chloride (Hartley, Biochem.J. 1970, 119, 805).
Glycine (from insulin A chain), phenylalanine (from insulin B chain) and lysine (from lysyl-alanine ) were found.
A second aliquot was examined by paper electrophoresis in acetic acid/formic acid at pH 2.1 (20 ml. formic acid, 80 ml. acetic acid made up to 1 litre with water) and showed H-Lys-Ala-OH, and another component (mobilities relative to ;■ £ -DNP-lysine 2.9 and 1.5 respectively). Elution of the second component and N-terminal amino-acid analysis revealed glycine and phenylalanine. Total amino-acid analysis gave integral amino-acid ratios of aspartic acid 3, serine 3j threonine 2, glutamic acid 7, proline 1, glycine 4, alanine 1, valine 4, isoleucine 2, leucine 6, phenylalanine 3, tyrosine histidine 2, and arginine 1, together with cysteine in an amount which was not determined precisely. The compound thus differs from porcine insulin in having no lysine and only one ' residue of alanine.
A third aliquot was applied to the top of the resin column of a Locarte Amino-acid Analyser (Locarte Ltd., 24 Emperor's Gate, London S.W.7) and the (23 cm.) resin column eluted in the usual way at 55°C. with the programme, 90 min. (pH. 3-28), 55 min. (pH 4.25), 155 min. (pH 6.65) in which insulin appears after 23^ minutes, Lys-Ala after 29 30 255 minutes, and des-Lys -Ala -porcine insulin after 223 minutes. Only two peaks corresponding to des-Lys 29-Ala30-porcine insulin and Lys-Ala were detected.
The remainder of the incubation mixture was applied to a column (60 x 0.9 cm.) of porous cross-linked dextran gel ('Sephadex' G-50) equilibrated with 0.1 M ammonium carbonate. The column was developed with 0.1 M ammonium carbonate at a flow rate of 3 ml./hr. and fractions of 30 drops (1 ml.) were collected. The fractions were assayed for peptide material by measuring the U.V. absorption at 280 nm, and fractions 25-35 containing the main peak were combined and lyophilised to give des-Lys 29-Ala30-porcine insulin.
Example 2 Porcine insulin which had been crystallised 10 times was dissolved in 0.1 M ammonium bicarbonate containing calcium chloride to give a solution containing 2 mg. of insulin per ml. and a calcium chloride concentration of -4 3 x 10 molar. Portions of this solution were then incubated at pH 8.2, 37°C. for 40 hours with amounts of AM protease giving the following enzyme/substrate ratios: 1/625, I/I25O, I/25OO and 1/5000. Analysis of the incubation mixtures at intervals by the techniques described in Example 1 showed completed cleavage in each case apart from the 1/5000 reaction where 88% cleavage was obtained at the end of the experiment .
Example 3 Porcine insulin which had been crystallised 10 times was dissolved in buffers prepared from ammonia and acetic acid of pH 4.0, 6.0, 8.0 and 10.0 containing calcium chloride to -4 give 2 mg./ml. of insulin and 3 x 10 molar calcium chloride. The solutions were incubated with AM protease at a 1/100 enzyme/substrate ratio at 37°C. for 6 hours. Analysis as in Example 2 showed that cleavage was taking place in each case.
Example 4 Porcine insulin which had been crystallised 10 times was dissolved in 0.1 M ammonium bicarbonate buffer of pH 8.2 containing calcium chloride to give a solution containing -4 2 mg./ml. of insulin and 3 x 10 molar calcium chloride.
Portions of the solution were incubated with AM protease at an enzyme/substrate ratio of 1/1000 for 3 hours at temperatures of 23°C, 37°C, 45°C, and 55°C Analysis as in Example 2 showed complete cleavage at 37°C. and 45°C, approximately 50% cleavage at 55°C. and a small amount of cleavage at 23°C. Example 5 A solution of porcine insulin [120 mg. - once crystallised porcine insulin purified by gel filtration (Sephadex G-50) in 0.1 M ammonium carbonate] in water (14 ml.), adjusted to pH 8.0 and containing 3 x 10 M calcium chloride was incubated at 37°C. with AM protease (120 yg. ) for 5 hours.
During the incubation, the pH was kept at 8.0 by the automatic addition of 0.005 sodium hydroxide solution. The resulting solution was applied to a column (100 x 1.4 cm.) of porous cross-linked dextran gel ('Sephadex' G-50) and the column developed with 0.1 M ammonium carbonate at a flow rate of 13 ml./hr. at 4°C. Fractions of 150 drops (5 ml.) were collected and assayed for peptide material by measuring their U.V. absorption at 280 nm. The fractions (22-30) containing 29 the main peak were combined and lyophilised to give des-Lys - Ala30-porcine insulin (100 mg.). On polyacrylamide gel electrophoresis at pH 8.9, this material appeared as a single component when stained with amido black. It had a mobility towards the anode of 1.2 relative to that of porcine insulin. It also gave the same integral amino-acid ratios as found in Example 1.
Example 6 A solution of porcine insulin (1 mg.) in 0.1 M ammonium bicarbonate buffer of pH 8.2 (1 ml.) was applied to the top of a column (10 x 0.5 cm.) containing 3 ml. of % agarose gel beads on to which had been covalently bound 5mg. of AM protease and equilibrated in the same ammonium bicarbonate buffer at 22°C. The column was eluted with ammonium bicarbonate buffer at a flow rate of 7 ml./hr. for 1 hour and the fractions assayed for peptide material by measuring the U.V. absorption at 280 nm. The fractions ¾ containing peptide material were combined and lyophilised to give des-Lys29-Ala30-porcine insulin having the same physical properties as the product of Example 5.
The agarose gel having AM protease bound to it was prepared as follows :- A suspension of 3 ml. of k% agarose gel beads ('Sepharose' 4B) in 10 ml. of water was stirred with 450 mg. of cyanogen bromide for 20 minutes while the pH of the mixture was maintained at 10-11 by the addition of 4N sodium hydroxide. The suspension was then mixed with ice and washed with 2 1. of a cold pH 8.0 buffer solution containing sodium bicarbonate (0.1 M) and sodium chloride (1.0 M) in water. The washed suspension was then stirred with 13.5 ml. of a solution of AM protease (5 mg. ) in the above pH 8.0 buffer at 110C. for 12 hours. The solid was washed with 1 1. of the above pH 8.0 buffer, and then kept in a 1 M solution of ethanolamine at pH 8,0 for 2 hours. The solid was washed with (a) 0.1 M sodium acetate/acetic acid buffer of pH H.O containing 1.0 M sodium chloride and then (b) 0.1 M sodium borate buffer of pH 8.5 containing 1.0 M sodium chloride, and the washings with (a) and then (b) repeated four times. The agarose beads containing covalently bound enzyme were then equilibrated With 0.1 M ammonium bicarbonate of pH 8.2.
Example 7 Solutions of porcine insulin (10 x crystallised) containing 1 mg./ml. were incubated at pH 8.0 and 40°C. for 2 hours w-ith AM protease at an enzyme/substrate ratio of 1/1000 in the presence of magnesium chloride at concentrations -1 -2 -3 -4 of 10 , 10 , 10 and 10 molar respectively. Analysis as in Example 2 showed 90% cleavage with 10_1 molar Mg, 75% -2 -3 cleavage with 10 and 10 J molar Mg. and 6 $ cleavage with -4 10 molar Mg. In the absence of magnesium, 68% cleavage took place.
Example 8 A solution of crystalline bovine insulin (150 mg.) in water (2 ml .), adjusted to pH 8.3 and containing 10 M calcium chloride, was incubated with AM protease (l40 yg. ) for 3 hours at 37°C. During the incubation, the pH was kept at 8.3 by the automatic addition of 0.02 M sodium hydroxide solution. An aliquot of the solution (10 μΐ.) was examined using the amino-acid analyser as described in example 1, but with the programme 1 min. (pH 3.28), 1 min. (pH 4.25), 60 min. (pH 6.65) then the column regeneration cycle. The insulin 29 3i peak (elution time 90 min.) was absent, whereas des-Lys -Ala bovine insulin (elution time 80 min.) and Lys-Ala (elution time 120 min.) were both present. The incubated solution was then lyophilised, and the solid dissolved in M acetic acid (2 ml.). This solution was subjected to gel filtration at 4°C. as described in example 5 but with M acetic acid as solvent. The fractions comprising the main peak as measured ·'. by U.V. absorption at 280 nm. were combined and lyophilysed 29 30 to give des-Lys ^-Ala -bovine insulin (113 mg.). On poly- acrylamide gel electrophoresis (pH 8.9) this material appeared as a single component when stained with amido black. It had a mobility of 1.2 times that of bovine insulin towards the anode. Total amino-acid analysis gave the same integral amino-acid ratios as bovine insulin apart from there being no lysine and only two alanine residues. Only glycine and phenylalanine were detected as N-terminal amino-acids by the "dansylation" technique described in Example 1.
Example 9 Once crystallised porcine insulin (150 mg.) was dissolved in water by the addition of N ammonium hydroxide, and the solution made up to 3.0 ml. with 0.1M ammonium bicarbonate. AM protease solution (150 yg., 0.5 ml.) was added, and the solution was kept at 37°C. for 11 hours.
Analysis of an aliquot of the digest by the technique described in Example 8 showed that digestion was complete. The solution was diluted with 0% v/v aqueous acetic acid (3 ml.), and the resulting solution was applied to a column of 'Sephadex' G 50 (l60 x 2.0 cm.). The column was eluted with 2055 v/v aqueous acetic acid, and the eluate was monitored by measuring the U.V. absorption at 280 nm. Fractions of 300 drops were collected with the flow rate at 15 ml. per hour. The insulin peak appeared between fractions 45-56 » these fractions were 29 30 combined and dried to give des-Lys -Ala^ -porcine insulin (135 mg). Under these conditions AM protease labelled with 1-125 appeared between fractions 36-^3.
Claims (28)
1. A polypeptide of the formula"- Gly.Ile.Val.Glu.Gln.Cyf~s.Csys~.RT.Sser".R7.C1ys.Ser.Leu.Tyr.Gln.Leu.Glu.Asn.Tyr.Cys.Asn s ' , X S ? / Phe.Val.Asn.Gln.His.Leu.Cys.Gly.Ser.His.Leu.Val.Glu.Ala.Leu.Tyr.Leu.Val.Cys.Gly.Glu -Arg.Gly.Phe.Phe.Tyr.Thr.Pro i 2 1 wherein either R is threonine and is isoleucine, or R is alanine and R 2 is valine. 29 SO
2. Des-Lys -Ala *porcine insulin ^ 29 so
3. Des-Lys -Ala -bovine insulin 29 30
4. A process for the preparation of des-Lys -Ala -porcine insulin from porcine insulin which comprises exposing the porcine insulin in an aqueous medium to the action of a lysine specific amino-endopeptidase ffoolllloowweedd bbyy sseeppaarraattiioonn ooff tthhee ddeess--LL]ys -Ala -porcine insulin from the remaining enzyme and lysyl-alanine.
5. A process for the preparation of des-Lys -Ala -bovine insulin from bovine insulin which comprises exposing the bovine insulin in an aqueous medium to the action of a lysine specific amino-endopeptidase 29 3- ffoolllloowweedd bbyy sseeppaarraattiioonn ooff tthhee ddeess--LL]ys *Ala -bovine insulin from the remaining enzyme and lysyl-alanine.
6. A process as claimed in claim 4 wherein the porcine insulin used as starting material is in the form in which it is normally available, and the des-Lys29-Ala30-porcine insulin is separated from the remaining enzyme,lysyl-alanine and oligopeptides.
7. A process as claimed in claim 4 wherein the bovine insulin used as starting material is in the form in which it is normally available, and the des-Lys29-Ala3--bovine insulin is separated from the remaining enzyme, lysyl-alanine and oligopeptides. 437S1/2
8. A process as claimed in any one of claims 4 to 7 wherein the lysine specific amino-endopeptidase is AM-protease.
9. A process as claimed in cijcic 8 wherein the exposure to the enzyme is carried out in a solution at a pH of 3-10, and a temperature of 10eC to 60eC.
10. A process as claimed in claim 9 wherein the pH is from 7 to 9, the temperature from 30°C to 50°C, and the concentration of insulin is near its solubility in the incubation medium and the enzyme/substrate ratio is from 1/1000 to 1/10,000.
11. A process as claimed in any one of claims 4-10 which is carried out in the presence of calcium or magnesium ions.
12. A process as claimed in any one of claims 4 to 11 wherein the enzyme is used in a form in which it is bound to a support.
13. A process as claimed in claim 12 wherein the enzyme AM protease is bound to an agarose support by the use of cyanogen bromide.
14. A process as claimed in any one of claims 4 to 13 wherein the separation is carried out by passing the incubation mixture through a molecular sieve.
15. A process as claimed in claim 14 wherein the molecular sieve is a cross-linked dextran gel or polyacrylamide gel suitable for fractionating compounds of molecular weight 5,000-10,000.
16. Des-Lys 29-Ala30-porcine insulin whenever prepared by the process of any of claims 4 and 8 to 15.
17. * Des-Lys 29-Ala30-bovine insulin whenever prepared by the process of any of claims 5 and 8 to 15.
18. Des-Lys 29-Ala30»porcine insulin whenever prepared by the process of claim 6.
19. Des-Lys 29-Ala30-bovine insulin whenever prepared by the process of claim 7. 4S751/2
20. An injectable formulation comprising des-Lys29-Ala30-porcine insulin and a pharmaceutically acceptable diluent or solvent.
21. An injectable formulation comprising des-Lys 29-Ala3Θ-bovine insuli and a pharmaceutically acceptable diluent or solvent.
22. An injectable formulation comprising the product claimed in claim 18 and a pharmaceutically acceptable diluent or solvent.
23. An injectable formulation comprising the product claimed in claim 19 and a pharmaceutically acceptable diluent, or solvent.
24. A polypeptide as claimed in claim 1 substantially as described in any one of Examples X to 6.
25. A polypeptide as claimed in claim 1 substantially as described in Example 7,8 or 9.
26. A process as claimed in claim 4 or 6 substantially as described in any one of Examples 1-6.
27. A process as claimed in claim 4 or 6 substantially as described in Example 7 or 9.
28. A process as claimed in claim 5 or 7 substantially as described in Example.8. S.HOROWITZ S'CO. AGENTS FOR APPLICANTS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5974272 | 1972-12-28 | ||
GB438773*[A GB1426061A (en) | 1972-12-28 | 1973-01-29 | Polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
IL43751A0 IL43751A0 (en) | 1974-03-14 |
IL43751A true IL43751A (en) | 1977-01-31 |
Family
ID=26239087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL43751A IL43751A (en) | 1972-12-28 | 1973-12-04 | Des-lys29-ala30-insulins and their preparation |
Country Status (18)
Country | Link |
---|---|
US (1) | US3903069A (en) |
JP (1) | JPS5726760B2 (en) |
AT (1) | AT348152B (en) |
AU (1) | AU474971B2 (en) |
CA (1) | CA1009974A (en) |
CH (1) | CH599927A5 (en) |
DD (1) | DD110490A5 (en) |
DE (1) | DE2364883C2 (en) |
ES (1) | ES421864A1 (en) |
FR (1) | FR2212136B1 (en) |
GB (1) | GB1426061A (en) |
HU (1) | HU170437B (en) |
IE (1) | IE38539B1 (en) |
IL (1) | IL43751A (en) |
LU (1) | LU69075A1 (en) |
NL (1) | NL7317159A (en) |
PL (1) | PL91158B1 (en) |
SE (1) | SE404600B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55138391A (en) * | 1979-04-13 | 1980-10-29 | Shionogi & Co Ltd | New synthetic method of peptide derivative |
DK146482C (en) * | 1979-04-13 | 1986-10-06 | Shionogi & Co | METHOD FOR PREPARING A B30-THREONINE INSULIN |
EP0087238A1 (en) * | 1982-02-08 | 1983-08-31 | Biogen N.V. | Am improved method for preparing human insulin from non-human insulin |
DE3209184A1 (en) * | 1982-03-13 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | METHOD FOR CONVERTING PRAEPROINSULIN ANALOGS TO INSULINES |
US6673347B1 (en) | 1986-04-30 | 2004-01-06 | Gryphon Therapeutics | Polypeptide and protein derivatives and process for their preparation |
GB8610551D0 (en) * | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
US5716927A (en) * | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
AU641631B2 (en) * | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH471220A (en) * | 1964-05-09 | 1969-04-15 | Roehm & Haas Gmbh | Process for the production of an aminopeptidase which cleaves L-leucine amide, hypertensin and oxytocin |
-
1973
- 1973-01-29 GB GB438773*[A patent/GB1426061A/en not_active Expired
- 1973-11-22 IE IE2122/73A patent/IE38539B1/en unknown
- 1973-11-23 CA CA186,556A patent/CA1009974A/en not_active Expired
- 1973-11-28 AU AU62979/73A patent/AU474971B2/en not_active Expired
- 1973-11-30 US US420573A patent/US3903069A/en not_active Expired - Lifetime
- 1973-12-04 IL IL43751A patent/IL43751A/en unknown
- 1973-12-14 NL NL7317159A patent/NL7317159A/xx unknown
- 1973-12-14 CH CH1759373A patent/CH599927A5/xx not_active IP Right Cessation
- 1973-12-15 PL PL1973167350A patent/PL91158B1/pl unknown
- 1973-12-20 SE SE7317256A patent/SE404600B/en unknown
- 1973-12-21 DD DD175618A patent/DD110490A5/xx unknown
- 1973-12-26 JP JP744631A patent/JPS5726760B2/ja not_active Expired
- 1973-12-27 AT AT1084473A patent/AT348152B/en not_active IP Right Cessation
- 1973-12-27 FR FR7346550A patent/FR2212136B1/fr not_active Expired
- 1973-12-27 LU LU69075A patent/LU69075A1/xx unknown
- 1973-12-28 HU HUIE605A patent/HU170437B/hu unknown
- 1973-12-28 DE DE2364883A patent/DE2364883C2/en not_active Expired
- 1973-12-28 ES ES421864A patent/ES421864A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ES421864A1 (en) | 1976-08-01 |
CA1009974A (en) | 1977-05-10 |
PL91158B1 (en) | 1977-02-28 |
LU69075A1 (en) | 1974-03-07 |
AU6297973A (en) | 1975-05-29 |
DE2364883A1 (en) | 1974-07-04 |
AU474971B2 (en) | 1976-08-05 |
DD110490A5 (en) | 1974-12-20 |
HU170437B (en) | 1977-06-28 |
NL7317159A (en) | 1974-07-02 |
FR2212136A1 (en) | 1974-07-26 |
ATA1084473A (en) | 1978-06-15 |
JPS5726760B2 (en) | 1982-06-07 |
IL43751A0 (en) | 1974-03-14 |
FR2212136B1 (en) | 1978-01-06 |
SE404600B (en) | 1978-10-16 |
CH599927A5 (en) | 1978-06-15 |
DE2364883C2 (en) | 1984-07-19 |
US3903069A (en) | 1975-09-02 |
GB1426061A (en) | 1976-02-25 |
IE38539L (en) | 1974-06-28 |
JPS4994698A (en) | 1974-09-09 |
IE38539B1 (en) | 1978-04-12 |
AT348152B (en) | 1979-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Blombäck et al. | N-terminal disulphide knot of human fibrinogen | |
Black et al. | Structural features of liver microsomal NADPH-cytochrome P-450 reductase. Hydrophobic domain, hydrophilic domain, and connecting region. | |
Sara et al. | Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. | |
McMullen et al. | Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as. beta.-hydroxyaspartic acid | |
Sletten et al. | The Complete Amino‐Acid Sequence of Non‐Immunolobulin Amyloid Fibril Protein AS in Rheumatoid Arthritis | |
Ong et al. | The amino-terminal sequence of porcine pepsinogen | |
EP0561412B1 (en) | Parathyroid hormone derivatives | |
CA1172978A (en) | .alpha.-AMYLASE INACTIVATOR, A PROCESS FOR ITS PREPARATION, AN AGENT BASED ON THIS INACTIVATOR AND ITS USE | |
JPH0764875B2 (en) | Novel polypeptide having anticoagulant effect | |
Strydom et al. | Snake Venom Toxins: PURIFICATION, PROPERTIES, AND COMPLETE AMINO ACID SEQUENCE OF TWO TOXINS FROM RINGHALS (HEMACHATUS HAEMACHATUS) VENOM | |
Bornstein | Comparative sequence studies of rat skin and tendon collagen. II. Absence of a short sequence at the amino terminus of the skin α1 chain | |
Joubert | Snake venom toxins: the amino acid sequences of two toxins from Ophiophagus hannah (King Cobra) venom | |
Eylar et al. | Allergic encephalomyelitis: Cleavage of the C-tryptophyl bond in the encephalitogenic basic protein from bovine myelin | |
Dixon et al. | The isolation and structure of α-melanocyte-stimulating hormone from horse pituitaries | |
Ozols | Amino acid sequence of rabbit liver microsomal cytochrome b5 | |
Kramer et al. | Cocoonase: V. Structural studies on an insect serine protease | |
Fassina et al. | Autolysis of thermolysin: Isolation and characterization of a folded three‐fragment complex | |
US3903069A (en) | Polypeptides obtained by modification of porcine or bovine insulin | |
Markussen et al. | Rat‐Proinsulin C‐Peptides: Amino‐Acid Sequences | |
HU205145B (en) | Process for producing new superactive insulin analogs and pharmaceutical compositions comprising same as active ingredient | |
JPH08504820A (en) | Insulin analogue | |
Lind et al. | Complete Amino‐Acid Sequence of a Non‐neurotoxic, Non‐enzymatic Phospholipase A2 Homolog from the Venom of the Australian Tiger Snake Notechis scutatus scutatus | |
Chen et al. | Purification and characteristics of porcine growth hormone | |
Wong et al. | Studies on the nature of the inhibition by gossypol of the transformation of pepsinogen to pepsin | |
Malatesta et al. | Arrangement of subunit IV in beef heart cytochrome c oxidase probed by chemical labeling and protease digestion experiments |